TerminatedPHASE1, PHASE2NCT04579757
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Studying Anaplastic thyroid carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hutchmed
- Principal Investigator
- William Schelman, MDHutchmed
- Intervention
- Surufatinib and Tislelizumab _ Part 1(drug)
- Enrollment
- 87 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2024
Study locations (18)
- Arizona Oncology Associated, PC-HOPE, Tucson, Arizona, United States
- City of Hope, Duarte, California, United States
- Rocky Mountain Cancer Centers Midtown, Denver, Colorado, United States
- Johns Hopkins University - Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
- Emory University - Winship Cancer Institute, Atlanta, Georgia, United States
- Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
- Prisma Health - Upstate (ITOR), Greenville, South Carolina, United States
- Sarah Cannon, Nashville, Tennessee, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Mary Crowley Cancer Research, Dallas, Texas, United States
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
- Texas Oncology, P.A., Fort Worth, Texas, United States
- +3 more locations on ClinicalTrials.gov
Collaborators
BeiGene
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04579757 on ClinicalTrials.govOther trials for Anaplastic thyroid carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06790706IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersHospices Civils de Lyon
- RECRUITINGPHASE1NCT06902376XL092 and Cemiplimab in BRAF WT Thyroid CancerUNC Lineberger Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06235216Sacituzumab govitEcan in THYroid CancersGrupo Espanol de Tumores Neuroendocrinos
- RECRUITINGPHASE2NCT06374602Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid CancerSaint Petersburg State University, Russia
- RECRUITINGPHASE2NCT06362694Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF TherapySaint Petersburg State University, Russia
- RECRUITINGPHASE2NCT06007924A Study of Avutometinib and Defactinib in People With Thyroid CancerMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT06079333NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)Leiden University Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT05453799Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid CancerNorthwestern University